198
Participants
Start Date
November 30, 2014
Primary Completion Date
November 30, 2019
Study Completion Date
December 31, 2019
Ferrous fumarate
Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
ferric(III)carboxymaltose
Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
NOT_YET_RECRUITING
Medisch Centrum Alkmaar, Alkmaar
NOT_YET_RECRUITING
Flevoziekenhuis, Almere Stad
NOT_YET_RECRUITING
Meander Ziekenhuis, Amersfoort
RECRUITING
Onze Lieve Vrouwe Gasthuis, Amsterdam
RECRUITING
Sint Lucas Andreas Ziekenhuis, Amsterdam
NOT_YET_RECRUITING
Spaarne ziekenhuis, Amsterdam
NOT_YET_RECRUITING
VU medical center, Amsterdam
RECRUITING
Amsterdam
NOT_YET_RECRUITING
Gelre Ziekenhuis, Apeldoorn
NOT_YET_RECRUITING
Albert Schweizer Ziekenhuis, Dordrecht
NOT_YET_RECRUITING
Tergooi ziekenhuis, Hilversum
NOT_YET_RECRUITING
Haga Ziekenhuis, The Hague
RECRUITING
Academic Medical Center, Amsterdam
Collaborators (1)
Vifor Pharma
INDUSTRY
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER